
TSE:HHL
This summary was created by AI, based on 6 opinions in the last 12 months.
The Healthcare Leaders Income ETF (HHL-T) holds a diversified portfolio of approximately 20-23 major healthcare companies, with a significant allocation in pharmaceuticals, healthcare equipment, and biotech. Experts recognize the recent pressures on the U.S. healthcare sector, primarily driven by economic factors and concerns around drug pricing, particularly amid political changes. Despite the negativity surrounding the sector, some analysts suggest that the current entry point may be favorable, as they anticipate a market normalization in response to demographic trends. The ETF employs a covered call strategy, offering a compelling dividend yield of 9-10%, but opinions are mixed on whether this strategy outperforms direct ownership of the underlying stocks. Overall, there's a cautious optimism regarding the ETF's potential for income generation and diversification within a broader portfolio.
This invests in healthcare related securities, and believes the enhancement comes from an option strategy overlay. Like any other sector, this is fine when it is going up. This ETF tends to have a lot of volatility compared to some of the others. He doesn’t use this, so doesn’t know that much about it. It’s a fine product and he has no issues with it. It has a pretty significant yield, which tends to be what attracts a lot of people. Dividend yield of 8%+ right now.
A theme that he is very interested in. He doesn’t know what this REIT actually owns, but would assume you will have your pharmaceuticals, and hopefully the bio-technology space. Even if it doesn’t have bio-technology, you might want to look at having this in your portfolio, even at these levels. Yield is 7%, so he presumes they are writing covered calls against these positions.
The US healthcare bill having failed Friday puts some risk into the sector. He would be fine if it fell back to support levels, but would not step in today, otherwise it is a fine quality holding.